$ESMC
ESCALON MEDICAL CORP

2024 Q2 Form 10-Q Financial Statement

#000086266824000017 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $3.472M $2.696M
YoY Change 10.72% -21.51%
Cost Of Revenue $2.000M $1.579M
YoY Change 19.23% -8.26%
Gross Profit $1.472M $1.117M
YoY Change 0.94% -34.82%
Gross Profit Margin 42.39% 41.43%
Selling, General & Admin $1.161M $1.118M
YoY Change 7.87% 19.12%
% of Gross Profit 78.85% 100.07%
Research & Development $173.0K $155.8K
YoY Change -2.52% -16.1%
% of Gross Profit 11.75% 13.96%
Depreciation & Amortization $19.26K $3.580K
YoY Change 78.66% -69.0%
% of Gross Profit 1.31% 0.32%
Operating Expenses $1.334M $1.273M
YoY Change 6.4% 13.3%
Operating Profit $138.3K -$156.6K
YoY Change -32.5% -126.56%
Interest Expense -$3.900K $5.541K
YoY Change -40.28% 28.41%
% of Operating Profit -2.82%
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income $134.4K -$162.2K
YoY Change -32.24% -127.71%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $121.6K -$162.1K
YoY Change 6654.44% -127.71%
Net Earnings / Revenue 3.5% -6.02%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share $0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 7.415M shares 7.415M shares
Diluted Shares Outstanding 7.415M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $209.0K $564.7K
YoY Change -76.5% 3.75%
Cash & Equivalents $209.0K $564.7K
Short-Term Investments
Other Short-Term Assets $194.1K $166.6K
YoY Change -22.3% 2.68%
Inventory $1.613M $1.805M
Prepaid Expenses
Receivables $2.124M $1.359M
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.397M $4.152M
YoY Change -5.19% -5.01%
LONG-TERM ASSETS
Property, Plant & Equipment $48.88K $53.97K
YoY Change 43.49% 35.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $62.79K $62.79K
YoY Change 0.0% 0.0%
Total Long-Term Assets $361.1K $447.2K
YoY Change -46.14% -40.38%
TOTAL ASSETS
Total Short-Term Assets $4.397M $4.152M
Total Long-Term Assets $361.1K $447.2K
Total Assets $4.758M $4.599M
YoY Change -10.36% -10.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.357M $1.118M
YoY Change 12.58% 6.7%
Accrued Expenses $588.3K $589.9K
YoY Change -9.76% -32.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $37.35K $36.43K
YoY Change -7.07% -0.63%
Total Short-Term Liabilities $2.669M $2.629M
YoY Change -6.45% -5.27%
LONG-TERM LIABILITIES
Long-Term Debt $271.3K $278.8K
YoY Change -11.32% -11.76%
Other Long-Term Liabilities $8.070K $15.97K
YoY Change -96.23% -94.55%
Total Long-Term Liabilities $279.4K $294.7K
YoY Change -46.27% -51.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.669M $2.629M
Total Long-Term Liabilities $279.4K $294.7K
Total Liabilities $2.948M $2.924M
YoY Change -12.59% -13.61%
SHAREHOLDERS EQUITY
Retained Earnings -$68.54M -$68.68M
YoY Change 0.18% 0.12%
Common Stock $7.415K $7.415K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.810M $1.675M
YoY Change
Total Liabilities & Shareholders Equity $4.758M $4.599M
YoY Change -10.36% -10.19%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $121.6K -$162.1K
YoY Change 6654.44% -127.71%
Depreciation, Depletion And Amortization $19.26K $3.580K
YoY Change 78.66% -69.0%
Cash From Operating Activities -$339.9K $175.2K
YoY Change -195.76% -27.25%
INVESTING ACTIVITIES
Capital Expenditures $9.250K -$9.250K
YoY Change -238.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.250K $9.250K
YoY Change -238.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.530K -10.14K
YoY Change -31.41% 210.09%
NET CHANGE
Cash From Operating Activities -339.9K 175.2K
Cash From Investing Activities -9.250K 9.250K
Cash From Financing Activities -6.530K -10.14K
Net Change In Cash -355.7K 174.3K
YoY Change -202.96% -24.5%
FREE CASH FLOW
Cash From Operating Activities -$339.9K $175.2K
Capital Expenditures $9.250K -$9.250K
Free Cash Flow -$349.1K $184.4K
YoY Change -198.36% -21.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1578727 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Escalon Medical Corp.
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
common stock, $0.001 par value
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
889674 usd
CY2023Q1 us-gaap Revenues
Revenues
3434314 usd
us-gaap Revenues
Revenues
8509738 usd
us-gaap Revenues
Revenues
9044619 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1720853 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
938161 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3401902 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3108177 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185750 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
515213 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
641316 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2844764 usd
us-gaap Costs And Expenses
CostsAndExpenses
8752517 usd
us-gaap Costs And Expenses
CostsAndExpenses
8770963 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
589550 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-242779 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
273656 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-6043 usd
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
6063607 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000862668
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7415329 shares
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-20127
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
PA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0272839
dei Entity Address Address Line1
EntityAddressAddressLine1
435 Devon Park Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Wayne
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
dei City Area Code
CityAreaCode
(610)
dei Local Phone Number
LocalPhoneNumber
688-6830
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
564707 usd
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
256390 usd
CY2024Q1 us-gaap Accounts Receivable Gross
AccountsReceivableGross
1491827 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
132624 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
1359203 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1804929 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
166600 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
4151829 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53971 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
276089 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
54355 usd
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
62787 usd
CY2024Q1 us-gaap Assets
Assets
4599031 usd
CY2024Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
33262 usd
CY2024Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
3172 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1118057 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
589877 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
112389 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
282950 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
403069 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
86333 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2629109 usd
CY2024Q1 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
135483 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15974 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
294746 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2923855 usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
645000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
7415 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68679282 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1675176 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4599031 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4835402 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5021470 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1117534 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155848 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
2852109 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-156608 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
5541 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
4315 usd
us-gaap Interest Expense
InterestExpense
16888 usd
us-gaap Interest Expense
InterestExpense
15188 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-162149 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
585235 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
585235 usd
us-gaap Net Income Loss
NetIncomeLoss
-259667 usd
us-gaap Net Income Loss
NetIncomeLoss
258468 usd
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12830 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
13006 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
38842 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
38735 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-174979 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
572229 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-298509 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
219733 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13478936 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13478936 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1934843 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1913646 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-76321 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1837325 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-162149 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1675176 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1478017 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-320724 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1157293 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1151250 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
585235 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1736485 usd
us-gaap Net Income Loss
NetIncomeLoss
-259667 usd
us-gaap Net Income Loss
NetIncomeLoss
258468 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
20354 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-93400 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26763 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34424 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
227558 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
215772 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-274164 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
107573 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
216940 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
61238 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-83189 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27798 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87453 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35375 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-62101 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-33063 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-244817 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-226404 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23158 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-36985 usd
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-792 usd
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-42955 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-262900 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29781 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31038 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6687 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7155 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31038 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13842 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
27853 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3165 usd
esmc Repayment Of Eidl Loan
RepaymentOfEIDLLoan
3079 usd
esmc Repayment Of Eidl Loan
RepaymentOfEIDLLoan
2686 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-30932 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5851 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-324870 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49474 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1145967 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
850034 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
821097 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
800560 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
564707 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
544320 usd
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
256390 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
256240 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
821097 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
800560 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
889674 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
593869 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
256293 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
256165 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1145967 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
850034 usd
us-gaap Interest Paid Net
InterestPaidNet
16985 usd
us-gaap Interest Paid Net
InterestPaidNet
15697 usd
us-gaap Nature Of Operations
NatureOfOperations
Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</span></div>
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
132624 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
153878 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
133524 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
241349 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
153878 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
236349 usd
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-98400 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
20354 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-93400 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
900 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
900 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
132624 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
142949 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
132624 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
142949 usd
CY2024Q1 esmc Recognized Revenue That Was Included Within Prior Period Deferred Revenue
RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue
165000 usd
CY2023Q1 esmc Recognized Revenue That Was Included Within Prior Period Deferred Revenue
RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue
43000 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
esmc Recognized Revenue That Was Included Within Prior Period Deferred Revenue
RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue
440000 usd
esmc Recognized Revenue That Was Included Within Prior Period Deferred Revenue
RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue
300000 usd
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
316000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
259000 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
426000 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
332000 usd
CY2024Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
284000 usd
CY2023Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
185000 usd
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
560000 usd
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
425000 usd
CY2024Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
197000 usd
CY2023Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
149000 usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
583000 usd
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
462000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
403000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
295000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
403000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
295000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-162149 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
585235 usd
us-gaap Net Income Loss
NetIncomeLoss
-259667 usd
us-gaap Net Income Loss
NetIncomeLoss
258468 usd
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12830 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
13006 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
38842 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
38735 usd
CY2024Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-174979 usd
CY2023Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
572229 usd
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-298509 usd
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
219733 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-162149 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
585235 usd
us-gaap Net Income Loss
NetIncomeLoss
-259667 usd
us-gaap Net Income Loss
NetIncomeLoss
258468 usd
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12830 usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
13006 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
38842 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
38735 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-174979 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
572229 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-298509 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
219733 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
6063607 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13478936 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13478936 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6564820 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
157000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6564820 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6564820 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
157000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
157000 shares
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1027000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
882000 usd
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
388000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
86000 usd
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
650000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
881000 usd
CY2024Q1 us-gaap Inventory Gross
InventoryGross
2065000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
1849000 usd
CY2024Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
260000 usd
CY2024Q1 esmc Netpresentvalueofnewleasefuturepayments
Netpresentvalueofnewleasefuturepayments
298924 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M19D
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
260000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1805000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
1588000 usd
CY2018Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
645000 usd
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
esmc Preferred Stock Number Of Votes Per Share
PreferredStockNumberOfVotesPerShare
13 vote
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
us-gaap Common Stock Voting Rights
CommonStockVotingRights
77.81
CY2024Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2.15 shares
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
4,300,000
CY2024Q1 esmc Convertible Preferred Stock Percentage Of Outstanding Shares Of Common Stock Upon Conversion
ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion
0.3670
CY2018Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.0258
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
316173 usd
CY2024Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.1581
CY2023 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
277331 usd
CY2023Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.1387
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
600 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
307857 usd
CY2024Q1 esmc Interestportioninthefutureleasepayments
Interestportioninthefutureleasepayments
8933 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
84970 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
85324 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
254992 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
256084 usd
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
84970 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
85324 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
254992 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
256084 usd
CY2024Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
88224 usd
CY2023Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
86350 usd
us-gaap Short Term Lease Payments
ShortTermLeasePayments
262387 usd
us-gaap Short Term Lease Payments
ShortTermLeasePayments
256883 usd
CY2024Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
88224 usd
CY2023Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
86350 usd
us-gaap Short Term Lease Payments
ShortTermLeasePayments
262387 usd
us-gaap Short Term Lease Payments
ShortTermLeasePayments
256883 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
88514 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
212415 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3928 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1200 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1200 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0572
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31

Files In Submission

Name View Source Status
0000862668-24-000017-index-headers.html Edgar Link pending
0000862668-24-000017-index.html Edgar Link pending
0000862668-24-000017.txt Edgar Link pending
0000862668-24-000017-xbrl.zip Edgar Link pending
esmc-20240331.htm Edgar Link pending
esmc-20240331.xsd Edgar Link pending
esmc_2024331-10qex311.htm Edgar Link pending
esmc_2024331-10qex312.htm Edgar Link pending
esmc_2024331-10qex321.htm Edgar Link pending
esmc_2024331-10qex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
esmc-20240331_def.xml Edgar Link unprocessable
esmc-20240331_pre.xml Edgar Link unprocessable
esmc-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
esmc-20240331_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending
esmc-20240331_cal.xml Edgar Link unprocessable